SLS - Company ID 0001390478
SELLAS Life Sciences Group, Inc. trades as SLS and has a market capitalization of $2.73 B, making it the #1920 largest US-listed company by market value. This page tracks SELLAS Life Sciences Group, Inc. through 1,262 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin compressed from -881.9% to -4130.1% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-12 |
| Quarterly report | 10-Q | 2026-05-12 |
| SCHEDULE 13G/A | - | 2026-04-24 |
| Annual report to shareholders | ARS | 2026-04-23 |
| Proxy materials | DEFA14A | 2026-04-23 |
| Proxy statement | DEF 14A | 2026-04-23 |
| SCHEDULE 13G/A | - | 2026-03-27 |
| S-3ASR | - | 2026-03-20 |
**Format:** Corporate Presentation and Fireside Chat
_– Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80_ _th_ _Event –_
_– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events –_
\- Preclinical data show that SLS009 lowers the apoptotic threshold in AML cells by suppressing critical survival pathways -
_\- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -_ _\- SELLAS’ Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized -_
The largest companies sharing SELLAS Life Sciences Group, Inc.'s SEC industry classification (pharmaceutical preparations).
SELLAS Life Sciences Group, Inc. (SLS) has a market capitalization of $2.73 B as of 2026-07-09, ranking #1920 among US-listed companies.
In its latest fiscal year SELLAS Life Sciences Group, Inc. reported a net loss of $26.86M.